Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma

Surgery (United States)

Volumn 154, Issue 6, 2013, Pages 1199-1205

  Zagzag, Jonathan ^a   Pollack, Aron ^a   Dultz, Linda ^a   Dhar, Shumon ^a   Ogilvie, Jennifer B ^a   Heller, Keith S ^a   Deng, Fang Ming ^a   Patel, Kepal N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THYROID PAPILLARY CARCINOMA;

ADULT; ANTIBODY SPECIFICITY; CARCINOMA; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTANT PROTEINS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; THYROID NEOPLASMS;

EID: 84887995180     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2013.06.020     Document Type: Article

References (23)

1. L. Davies, and H.G. Welch Increasing incidence of thyroid cancer in the United States, 1973-2002 Jama 295 2006 2164 2167
2. Y.E. Nikiforov, and M.N. Nikiforova Molecular genetics and diagnosis of thyroid cancer Nat Rev Endocrinol 7 2011 569 580
3. M.N. Nikiforova, and Y.E. Nikiforov Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis Expert Rev Mol Diagn 8 2008 83 95
4. A. Mathur, W. Moses, R. Rahbari, E. Khanafshar, Q.Y. Duh, and O. Clark Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study Cancer 117 2011 4390 4395
5. C. Li, K.C. Lee, E.B. Schneider, and M.A. Zeiger BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis J Clin Endocrinol Metab 97 2012 4559 4570
6. S.K. Kim, D.L. Kim, H.S. Han, W.S. Kim, S.J. Kim, and W.J. Moon Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules Diagn Mol Pathol 17 2008 118 125
7. H.S. Kim, J.O. Kim, D.H. Lee, H.C. Lee, H.J. Kim, and J.H. Kim Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma Oncol Rep 25 2011 1639 1644
8. H.J. Lee, J. Choi, T.S. Hwang, Y.K. Shong, S.J. Hong, and G. Gong Detection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system Am J Clin Pathol 133 2010 802 808
9. D. Capper, M. Preusser, A. Habel, F. Sahm, U. Ackermann, and G. Schindler Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody Acta Neuropathol 122 2011 11 19
10. D. Capper, A.S. Berghoff, M. Magerle, A. Ilhan, A. Wöhrer, and M. Hackl Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases Acta Neuropathol 123 2012 223 233
11. O. Koperek, C. Kornauth, and D. Capper Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma Am J Surg Pathol 36 2012 844 850
12. G.V. Long, J.S. Wilmott, D. Capper, A.S. Berghoff, R. Asari, and B. Niederle Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma Am J Surg Pathol 37 2012 61 65
13. M. Preusser, D. Capper, and A.S. Berghoff Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors Appl Immunohistochem Mol Morphol 21 2013 162 167
14. M. Preusser, A.S. Berghoff, D. Capper, R. Horvat, F. Wrba, and M. Schindl No Evidence for BRAF-V600E mutations in gastroeosophageal tumors: results from a high-throughput analysis of 534 cases using a mutation-specific antibody Appl Immunohistochem Mol Morphol 21 2013 159 164
15. L. Xu, J.L. Zhou, M. Cohen, D. Bar-Sagi, and K.N. Patel Spry2 expression correlates with BRAF mutation in thyroid cancer Surgery 148 2010 1282 1287 discussion 1287
16. M. Xing BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications Endocr Rev 28 2007 742 762
17. K.C. Lee, C. Li, E.B. Schneider, Y. Wang, H. Somervell, and M. Krafft Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery 152 2012 977 983
18. J.K. Nam, C.K. Jung, B.J. Song, D.J. Lim, B.J. Chae, and N.S. Lee Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg 203 2012 436 441
19. Y.E. Nikiforov, N.P. Ohori, S.P. Hodak, S.E. Carty, S.O. LeBeau, and R.L. Ferris Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples J Clin Endocrinol Metab 96 2011 3390 3397
20. Y.E. Nikiforov, L. Yip, and M.N. Nikiforova New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers Clin Cancer Res 19 2013 2283 2288
21. G.M. Howell, M.N. Nikiforova, S.E. Carty, M.J. Armstrong, S.P. Hodak, and M.T. Stang BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer Ann Surg Oncol 20 2013 47 52
22. A.L. Melck, L. Yip, and S.E. Carty The utility of BRAF testing in the management of papillary thyroid cancer Oncologist 15 2010 1285 1293
23. L. Yip, C. Farris, A.S. Kabaker, S.P. Hodak, M.N. Nikiforova, and K.L. McCoy Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies J Clin Endocrinol Metab 97 2012 1905 1912